#USA #Chicago #Orphalan #Wilson Disease #Trientine Therapy

Orphalan Launches Global Phase 3 TRADITiONAL Study for Wilson Disease Treatment

Orphalan Inc., a prominent name in the pharmaceutical industry, has recently announced the initiation of the TRADITiONAL Study, a significant global Phase 3 clinical trial aimed at assessing a novel once-daily formulation of trientine tetrahydrochloride. This investigational therapy targets the treatment of Wilson disease, a rare genetic disorder that impacts copper metabolism in the body. The study is poised to provide new insights into treatment efficacy and safety compared to the existing option, D-penicillamine.

Understanding Wilson Disease

Wilson disease is characterized by an accumulation of copper in the body due to a defect in the ATP7B gene, which can lead to severe complications affecting the liver, brain, and other vital organs if left untreated. Patients typically require lifelong therapy to manage the condition effectively. Traditional treatment regimens often involve complex medication schedules, which can hinder patient adherence and overall quality of life.

The TRADITiONAL Study

The TRADITiONAL Study is an international clinical endeavor that will involve several key sites in the United States, including the University of Colorado Anschutz School of Medicine, Yale University School of Medicine, and the University of Michigan Medical Center. It is designed as a randomized, parallel-group, open-label study focusing on both symptomatic and asymptomatic patients aged 8 years and older. Eligible participants will either be treatment-naïve or will have only received zinc salts for a short period.

Over the course of 48 weeks, participants will receive either the investigational trientine formulation or D-penicillamine, with the study evaluating various factors including efficacy, safety, tolerability, and patient-reported treatment satisfaction. The outcomes are anticipated to be pivotal in determining the feasibility of a simplified treatment approach for Wilson disease patients.

Commitment to Patient Needs

Omar Kamlin, the Chief Medical Officer at Orphalan, emphasized the necessity for lifelong treatment strategies for Wilson disease, noting that current options can be overwhelming and detrimental to patient adherence. The initiation of this study signifies Orphalan's dedication to addressing the unmet needs of individuals affected by this challenging condition. The trial's potential to streamline therapy aligns with Orphalan's overarching goal of enhancing patient care and treatment accessibility.

Expanding Global Reach

In addition to the initial study sites in the U.S., the TRADITiONAL Study aims to expand its enrollment to several international locations, including China, Pakistan, and Saudi Arabia. As more centers join the study, the company hopes to gather a diverse pool of data to strengthen the trial's findings, paving the way for potentially greater insights into the management of Wilson disease.

For those interested in learning more about the TRADITiONAL Study, additional details can be found on ClinicalTrials.gov under the identifier NCT07465718.

About Orphalan

Orphalan is dedicated to developing therapies for rare diseases, with a particular focus on Wilson disease and other conditions such as infantile epileptic spasms syndrome (IESS). With a commitment to patient-centered care, the company collaborates closely with healthcare professionals and communities to ensure that specialized treatment options are available for those afflicted by rare diseases. With their ongoing research and development efforts, Orphalan remains at the forefront of innovation in the pharmaceutical landscape.

The TRADITiONAL Study not only stands as a beacon of hope for current and future patients but also reinforces the critical need for research and advancements in treatments for rare diseases.